Y-mAbs Therapeutics (YMAB) PT Lowered to $7 at Morgan Stanley
Tweet Send to a Friend
Morgan Stanley analyst Michael Ulz lowered the price target on Y-mAbs Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
